Union Biotech

UNION therapeutics is a clinical-stage pharmaceutical company focused on developing novel treatments for immunology and infectious diseases. The company's lead candidate, orismilast, is a high-potency, next-generation PDE4 inhibitor being evaluated for inflammatory skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. UNION utilizes a proprietary chemistry platform to identify molecules with dual antimicrobial and immunomodulatory properties, aiming to address significant unmet medical needs. The company has established strategic partnerships, including a major licensing agreement with Innovent Biologics for the development of orismilast in China.